Chapter 2
The Cell Biology of the SARS Coronavirus Receptor, Angiotensin-Converting Enzyme 2

Daniel W. Lambert

Abstract The identification of angiotensin-converting enzyme 2 (ACE2) as a cellular receptor for the SARS coronavirus (SARS-CoV) rejuvenated research into what was regarded by some as a minor player in the renin–angiotensin system. The discovery of its double life led to breathtaking advances in the understanding of virtually all aspects of its biology, including its structure, physiological and pathophysiological roles and cell biology. ACE2, like its well-known homologue, ACE, is a metallopeptidase which resides on the cell surface of the epithelial, and sometimes endothelial, cells of the heart, kidney, testes, lung and gastrointestinal tract. It is a type I transmembrane protein with a large catalytic extracellular domain which acts as both a peptidase and a viral receptor. This extracellular domain can be cleaved from the cell surface by other peptidases, modulating its activity. The levels of the enzyme on the cell surface are also thought to be regulated by internalisation on S-protein binding and by clustering in membrane microdomains known as lipid rafts. This chapter summarises the current understanding of how the cell biology of ACE2 is regulated and may influence and determine its function, and concludes by discussing the future challenges and opportunities for studies of this increasingly important enzyme.

2.1 Introduction

Angiotensin-converting enzyme 2 (ACE2) was first identified in 2000 simultaneously by two groups using distinct methodologies (Donoghue et al. 2000; Tipnis et al. 2000). Its close mammalian homologue, angiotensin-converting enzyme (ACE), is a well-characterised angiotensinase and prominent therapeutic target in

D.W. Lambert
Department of Oral and Maxillofacial Pathology, Faculty of Medicine, Dentistry and Health, University of Sheffield, UK S10 2TA
e-mail: d.w.lambert@sheffield.ac.uk
hypertension, leading to a concentration of early studies of ACE2 on its substrate specificities and role in the renin–angiotensin system (RAS). Like ACE, ACE2 is a zinc metallopeptidase which is able to hydrolyse a wide variety of substrates. Of these, the best studied in the context of ACE2 are angiotensin I (Ang I) and angiotensin II (Ang II), peptides involved in regulating blood pressure and tissue fibrosis. Although able to cleave both peptides, it has become clear that the mitogenic and hypertensive peptide Ang II is the predominant physiological substrate of ACE2, being cleaved to the vasodilatory peptide angiotensin-(1–7). This suggested that ACE2 is therefore likely to have a beneficial role in cardiovascular disease, a finding which slowed research efforts due to its unsuitability as a target for conventional pharmacological intervention. The discovery of a role for ACE2 as a receptor for the SARS coronavirus (SARS-CoV) (Li et al. 2005), however, led to a reinvigoration and diversification of research effort toward understanding the tissue distribution and cell biology of ACE2.

2.2 Clues from Homologous Proteins

ACE2 is an 805-amino-acid glycoprotein bearing significant sequence homology in its N-terminal domain to somatic ACE and in its cytoplasmic, C-terminal domain to collectrin, also known as Tmem27 (Fig. 2.1). Analysis of the amino acid sequence of ACE2 reveals a putative signal peptide and transmembrane domain, indicating that it, like its homologue ACE, is expressed as a type I (N-terminal domain extracellular) transmembrane protein. The extracellular domain shares significant sequence identity with the equivalent region of ACE, but unlike somatic ACE, contains only a single HEMGH zinc-binding catalytic motif, as is the case with the germinal isoform of ACE (Fig. 2.1). The intracellular, carboxy-terminal region of ACE2, however, shares no homology with ACE but instead closely resembles that

![Fig. 2.1 Alignment of ACE2 sequence with homologous proteins. Regions of homology are indicated with shading. All four proteins contain signal peptides and transmembrane regions, but collectrin contains no catalytic residues. ACE2 is homologous with both the N terminus of somatic ACE and the C terminus of collectrin.](image-url)
of collectrin, a non-catalytic protein with a small extracellular domain expressed in the kidney (Zhang et al. 2001) and pancreas (Fukui et al. 2005). This structure suggests the possibility that ACE2 may represent a gene fusion product between ACE and collectrin. The regions of homology between the four proteins are further illustrated in Fig. 2.2, which illustrates the orientation of the proteins in the plasma membrane.

The membrane localisation of ACE2 and ACE is in keeping with their roles in the RAS, allowing their extracellular catalytic sites to cleave circulating angiotensin (and other) peptides. In polarised epithelial cells in culture, ACE2 is trafficked predominantly to the apical membrane, with little detectable in the basolateral compartment (Warner et al. 2005). Interestingly, ACE displays a different localisation, being equally distributed between apical and basolateral membrane compartments. While the mechanisms responsible for this difference have yet to be identified, it is likely that distinct targeting motifs may reside in the disparate cytoplasmic domains of the two proteins. This suggestion is reinforced by the primarily apical expression of collectrin (Zhang et al. 2001), which shares homology in its cytoplasmic domain with ACE2 but not ACE, in collecting duct epithelial cells in the kidney.

In vivo, ACE2 is expressed predominantly in the heart, kidneys and testes (Tipnis et al. 2000), and to a lesser extent the lung and gastrointestinal tract, with low levels detectable in most tissues (Hamming et al. 2004). In the heart, ACE2 is expressed predominantly in cardiac myofibroblasts (Guy et al. 2008), cardiac myocytes and endothelial cells (Burrell et al. 2005), although this distribution is reported to vary between species. In the kidney, ACE2 is expressed in proximal and distal tubular epithelial cells, with low levels detectable in the glomeruli. Immunohistochemical analysis demonstrates a predominantly membranous expression pattern for ACE2 in these cells, with immunoreactivity strongest in the apical brush
border (Brosnihan et al. 2003). These findings are in keeping with the observed localisation in polarised kidney epithelial cells in culture (Warner et al. 2005). In the lung ACE2 is primarily confined to the epithelium, with cell surface expression detected in Clara and type II cells, but is also found in smooth muscle and endothelial cells (Wiener et al. 2007). In lung epithelial cells grown in culture, ACE2 is expressed predominantly in the apical membrane compartment (Ren et al. 2006), in keeping with its role as a receptor for SARS-CoV.

2.3 Regulation of ACE2 Expression on the Cell Surface

The levels and function of cell-surface proteins may be controlled in a number of ways, including modulation of gene expression, shedding of the protein from the cell surface, internalisation and clustering in lipid microdomains within the plasma membrane. This chapter will concentrate on the mechanisms regulating the levels of the mature ACE2 protein on the cell surface.

2.3.1 Proteolytic Cleavage Secretion

Many membrane proteins, particularly type I transmembrane proteins, undergo a proteolytic cleavage secretion event, more commonly referred to as “shedding,” in which the ectodomain of the protein is cleaved by a proteinase, often a member of the matrix metalloproteinase (MMP) or a disintegrin and metalloproteinase (ADAM) families, and released into the extracellular milieu (illustrated in Fig. 2.3) (Huovila et al. 2005). This process may serve to release a ligand, allowing it to bind to its receptor (e.g., cytokines such as TNF-α), or simply to downregulate

![Diagram of Ectodomain shedding](image)

**Fig. 2.3** Ectodomain shedding. Many transmembrane proteins, particularly those with an extracellular amino-terminal domain, are subject to a “shedding” event in which an intramembrane proteinase cleaves the juxtamembrane region of the target protein (a), releasing its ectodomain into the extracellular milieu (b)
the levels or activity of a protein on the cell surface. ACE2 (along with its homologue ACE) is subject to such an ectodomain shedding event, releasing a catalytically active ectodomain, a process regulated by protein kinase C activation and involving a member of the ADAM family, TACE (TNF-α converting enzyme) (Lambert et al. 2005, 2008). While the physiological significance of this shedding event is not clear, increased levels of circulating ACE2 have been detected in cardiovascular disease (Shaltout et al. 2008), and the ability of cleaved (soluble) ACE2 to reduce SARS-CoV infectivity is well established (Li et al. 2003). Intriguingly, however, siRNA-mediated TACE downregulation reduces the ability of SARS to infect Huh7 cells (Haga et al. 2008), suggesting the role of ACE2 shedding in SARS infection is more complex than is readily apparent.

Commonly, the transmembrane regions of shed proteins are subsequently subject to further intramembrane cleavage, generating a short carboxy-terminal fragment, a process termed regulated intramembrane proteolysis (RIP) (Medina and Dotti 2003). It has been demonstrated for a number of proteins, most notably notch and Alzheimer’s precursor protein (APP) but also the ACE2 homologue, ACE (Fleming 2006), that this carboxy-terminal fragment is able to trigger signalling events leading to changes in the expression of target genes. Whether such a signalling mechanism occurs following ectodomain shedding of ACE2 remains to be established. The cytoplasmic domain of ACE2 is known, however, to have a regulatory role, both in terms of ectodomain shedding (Lambert et al. 2008) and SARS infectivity (Haga et al. 2008). Association of the cytoplasmic tail with a ubiquitous calcium-binding protein, calmodulin, reduces the release of its ectodomain suggesting a role for calmodulin in regulating ACE2 expression on the cell surface. The role of the cytoplasmic domain on SARS infection is controversial; Haga et al. (2008) recently reported that entry of SARS-CoV is dependent on the presence of the cytoplasmic domain of ACE2, a finding in direct contrast to those of Pohlmann et al. (2006) and Inoue et al. (2007) who suggest that entry is not dependent on the presence of this domain. These differences remain to be resolved but are likely due to the different experimental systems used.

2.3.2 The Role of Membrane Microdomains

It is thought that within the plane of plasma membranes, clusters of lipids such as sphingolipids and cholesterol form microdomains often termed lipid rafts. Although still somewhat controversial, a large body of evidence indicates that lipid rafts influence signalling and protein–protein interactions by partitioning and clustering proteins. Much of this evidence comes from studies in which cellular cholesterol is depleted using agents such as methyl-β-cyclodextrin. Cholesterol depletion alters the ability of a number of viruses to infect mammalian cells, including SARS-CoV. Studies by Glende et al. (2008) have revealed cholesterol dependence for SARS-CoV entry into cells on the presence of lipid rafts, possibly due to clustering of ACE2 into these microdomains. Furthermore, it has been
demonstrated that virus entry is mediated by internalisation of ACE2 upon S-protein binding into endosomes by a clathrin- and caveolin-independent mechanism involving lipid rafts (Wang et al. 2008). A degree of controversy remains about the role of membrane microdomains in regulating SARS-CoV entry, however, as others have failed to detect ACE2 in lipid raft preparations (Warner et al. 2005). The reasons for these discrepancies remain unclear, but are likely to be due to the use of heterologously- or endogenously-expressed ACE2 and/or differences in lipid raft preparation methodologies.

### 2.4 Conclusions and Future Perspectives

The serendipitous discovery of ACE2 as the cellular receptor for SARS-CoV rejuvenated studies analysing the cell biology of a protein previously thought by some only to be a minor player in the RAS. This reinvigoration of research not only led to important discoveries regarding the mechanisms regulating the expression of ACE2 at the cell surface, impacting on its function as the SARS-CoV receptor, but also helped stimulate studies which revealed an unexpectedly significant role for ACE2 in the RAS. Further work is required to fully elucidate the mechanisms regulating the cell surface function of ACE2; it is likely to interact with as-yet-unidentified proteins and may turn out to have intracellular signalling functions which influence its function and the function of other proteins. At present, most of the cell biological studies of ACE2 have been directed at analysing post-transcriptional events regulating its function. Changes in the levels of ACE2, however, have been identified in a wide variety of pathologies, suggesting that transcriptional and post-transcriptional regulatory mechanisms may also have an important role. Indeed, recent studies have indicated a number of pathways which may regulate ACE2 at the molecular level. Whatever the focus of future studies turns out to be, however, it seems unlikely that ACE2 has given up all its secrets yet.

### References

Brosnihan KB, Neves LA, Joyner J, Averill DB, Chappell MC, Sarao R, Penninger J, Ferrario CM (2003) Enhanced renal immunocytochemical expression of ANG-(1–7) and ACE2 during pregnancy. Hypertension 42:749–753

Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, Johnston CI (2005) Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26:369–375; discussion 322–364

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87:E1–E9

Fleming I (2006) Signaling by the angiotensin-converting enzyme. Circ Res 98:887–896
Fukui K, Yang Q, Cao Y, Takahashi N, Hatakeyama H, Wang H, Wada J, Zhang Y, Marselli L, Nammo T, Yoneda K, Onishi M, Higashiyama S, Matsuzawa Y, Gonzalez FJ, Weir GC, Kasai H, Shimomura I, Miyagawa J, Wollheim CB, Yangata K (2005) The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab 2:373–384

Glende J, Schwemmann-Wessels C, Al-Falah M, Pfefferle S, Qu X, Deng H, Drosten C, Naim HY, Herrler G (2008) Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology 381:215–221

Guy JL, Lambert DW, Turner AJ, Porter KE (2008) Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts. Exp Physiol 93:579–588

Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, Sasazuki T, Ishizaka Y (2008) Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry. Proc Natl Acad Sci USA 105:7809–7814

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ, van Goor H (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 203:631–637

Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM (2005) Shedding light on ADAM metalloproteinases. Trends Biochem Sci 30:413–422

Inoue Y, Tanaka N, Tanaka Y, Inoue S, Morita K, Zhuang M, Hattori T, Sugamura K (2007) Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J Virol 81:8722–8729

Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith A, Hooper NM, Turner AJ (2005) Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280:30113–30119

Lambert DW, Clarke NE, Hooper NM, Turner AJ (2008) Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett 582:385–390

Li W, Moore MJ, Vasileieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450–454

Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasileieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M (2005) Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 24:1634–1643

Medina M, Dotti CG (2003) RIPped out by presenilin-dependent gamma-secretase. Cell Signal 15:829–841

Pohlmann S, Gramberg T, Wegele A, Pyrc K, van der Hoek L, Berkhour B, Hofmann H (2006) Interaction between the spike protein of human coronavirus NL63 and its cellular receptor ACE2. Adv Exp Med Biol 581:281–284

Ren X, Glende J, Al-Falah M, de Vries V, Schwemmann-Wessels C, Qu X, Tan L, Tschernig T, Deng H, Naim HY, Herrler G (2006) Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. J Gen Virol 87:1691–1695

Shaltout HA, Figueroa JP, Rose JC, Diz DI, Chappell MC (2008) Alterations in circulatory and renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 in fetal programmed hypertension. Hypertension 53:404–408

Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:33238–33243

Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C (2008) SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 18:290–301
Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ (2005) Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem 280:39353–39362

Wiener RS, Cao YX, Hinds A, Ramirez MI, Williams MC (2007) Angiotensin converting enzyme 2 is primarily epithelial and is developmentally regulated in the mouse lung. J Cell Biochem 101:1278–1291

Zhang H, Wada J, Hida K, Tsuchiyama Y, Hiragushi K, Shikata K, Wang H, Lin S, Kanwar YS, Makino H (2001) Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem 276:17132–17139
Chapter 3

Structural Molecular Insights into SARS Coronavirus Cellular Attachment, Entry and Morphogenesis

Daniel R. Beniac and Timothy F. Booth

Abstract Coronavirus spikes have the largest mass of any known viral spike molecule. The spike is a type 1 viral fusion protein, a class of trimeric surface glycoprotein proteins from diverse viral families that share many common structural and functional characteristics. Fusion proteins are mainly responsible for host cell receptor recognition and subsequent membrane fusion, and may perform other roles such as virus assembly and release via budding. The conformational changes that occur in the spike of intact SARS coronavirus (SARS-CoV) when it binds to the viral receptor, angiotensin-converting enzyme 2 (ACE2) are described. Clues to the structural/functional relationships of membrane fusion have been made possible by the development of viral purification and inactivation methods, along with cryo-electron microscopy (cryo-EM) and three-dimensional (3D) image processing of many different images containing multiple views of the spikes. These methods have allowed study of the spikes while still attached to virions that are noninfectious, but fusionally competent. The receptor-binding and fusion core domains within the SARS-CoV spike have been precisely localized within the spike. Receptor binding results in structural changes that have been observed in the spike molecule, and these appear to be the initial step in viral membrane fusion. A working model for the stepwise process of receptor binding, and subsequent membrane fusion in SARS-CoV is presented. Uniquely, the large size of the SARS-CoV spike allows structural changes to be observed by cryo-EM in the native state. This provides a useful model for studying the basic process of membrane fusion in general, which forms an essential part of the function of many cellular processes.

T.F. Booth
Viral Diseases Division, National Microbiology Laboratory, Public Health Agency of Canada, 1015 Arlington Street, Winnipeg, Manitoba R3E 3R2, Canada
E-mail: Tim_Booth@phac-aspc.gc.ca

S.K. Lal (ed.), Molecular Biology of the SARS-Coronavirus,
DOI 10.1007/978-3-642-03683-5_3, © Springer-Verlag Berlin Heidelberg 2010
3.1 Structure of SARS Coronavirus (SARS-CoV)

The earliest coronavirus isolates were identified from mammalian and avian sources in the 1930s and 1940s (Beaudette and Hudson 1937; Doyle and Hutchings 1946; Cheevers and Daniels 1949). At this time, electron microscopy revealed prominent large spikes on the surface of virions, whose resulting crown-like appearance gave rise to the name coronavirus (Fig. 3.1). Coronaviruses have 4–5 structural proteins including the spike protein (S), envelope protein (E), membrane protein (M), nucleocapsid protein (N), and members of the coronavirus phylogenetic subgroup 2a have a shorter S protein called hemagglutinin esterase (HE). The SARS-CoV genome is unusually large at ~29.7 kb, and encodes 14 open reading frames for several proteins, (Marra et al. 2003; Rota et al. 2003). On the interior, the lipid envelope of SARS-CoV appears to have a gap observed as a low density in three-dimensional (3D) structures (Fig. 3.2) and then a more dense layer, which is presumably the surface of the nucleocapsid comprising mainly the N protein. Details of how this nucleocapsid is organized are not clear; however, the N protein is presumably anchored to the cytoplasmic side of the virion envelope via the

Fig. 3.1 EM images of γ-irradiated SARS-CoV. Immuno-EM with 10 nm gold confirmed the attachment of neutralizing antibodies to the spike (a, b), and the binding of soluble ACE2 to the spike (c). (d) SARS-CoV negative-stained with methylamine tungstate shows the virions to be spherical/pleomorphic, with the spikes clearly visible from the side perspective. (e) Cryo-EM provides additional details including the end-on perspective views of the spikes. (f) The central section of an electron tomogram of a negative-stained SARS-CoV clearly shows the viral envelope with the spikes attached. (g) Schematic model of SARS-CoV. Scale bars: (black) 1,000 Å, (white) 500 Å
M protein, which is a low abundance protein and may account for the “gap” of low density between the envelope and the nucleocapsid. Electron microscopic examination shows no evidence for supercoiled RNA such as that seen in paramyxoviruses and the interior appears amorphous by cryo-electron microscopy (cryo-EM); hence the arrangement whereby the RNA may be bound to the nucleocapsid protein is not clear.

A striking feature of the SARS-CoV spike is its huge mass (~500 kD per trimer). However, despite the size differences, the SARS-CoV spike performs the same fundamental task in viral entry to the host cell as other smaller type 1 viral fusion proteins, such as the influenza hemagglutinin (HA) (~220 kD per trimer). The SARS-CoV spike can be subdivided into four structural domains (from N to C terminus); two large external domains S1 and S2 are largely responsible for receptor binding and membrane fusion, respectively. In most type 1 viral fusion proteins the analogous peptides are generated by proteolysis of the spike precursor during the maturation process in the host cell, yielding two peptides with the fusion peptide on the N terminus of S2. In SARS-CoV the S1/S2 assignment is given based on sequence homology to other viral fusion proteins, although there appears to be no peptide cleavage. The final two small domains are comprised of a transmembrane domain, and a carboxyterminal cytoplasmic domain. The cell-surface molecule angiotensin-converting enzyme 2 (ACE2) is the receptor for the SARS-CoV S protein (Li et al. 2003) which is a relatively large macromolecule with a diameter of 70 Å. By comparison, the receptor for influenza HA, sialic acid, is much smaller with a 10 Å diameter.

One of the challenges of achieving structural molecular studies with native SARS-CoV is that it is classified as a biological safety level 3 organism, requiring handling in containment. However, once it was shown that specimens could be γ-irradiated with a sufficient dose (2 Mrad) for viral inactivation, while still preserving protein structure, it was possible to carry out cryo-EM of intact virions and to obtain the 3D structure of the native, unfixed virions and the spike, using single particle image processing and averaging from multiple images containing

---

**Fig. 3.2** Image analysis was employed to investigate the spike of SARS-CoV. (a) Image average of the virion clearly shows the lipid bilayer (Bi), a prominent gap (G), and the nucleocapsid (NC). (b) 2D class averages of the spike (S) presenting end-on and side-view perspectives. (c) 3D model of SARS-CoV, with a wedge cut out of it to reveal the nucleocapsid. Legend: (S) spike, green; (Bi) lipid bilayer, beige; (G) gap; (NC) nucleocapsid, red. Scale bar: 150 Å.
many different viewing angles of the molecule (Booth et al. 2005; Beniac et al. 2006). Immunolabeling showed that these virions were intact antigenically as well as structurally (Fig. 3.1) and still able to bind to the SARS-CoV receptor, ACE2.

### 3.2 Structure of the Coronavirus Spike

Cryo-EM coupled with 3D single-particle image analysis has been used to determine the structure of the SARS-CoV spike, and positioning of the binding of ACE2 to the spike (Beniac et al. 2006, 2007). Spikes on the surface of virus particles are readily imaged by cryo-EM in the frozen-hydrated native state (Fig. 3.1e). 3D image processing was carried out on selected spikes using single-particle image processing (Penczek et al. 1994; Frank et al. 1996; Beniac et al. 2006). The structures of both the spike and the spike–ACE2 complex have been solved to 18.5 Å resolution (Figs. 3.2 and 3.3; Beniac et al. 2006, 2007). The spike shows a striking structure, being about 180 Å in diameter and with three distinct lobes or domains 50 Å thick on each subunit of the trimer (similar in appearance to the blades of a propeller), and a thin stalk connecting the spike to the viral envelope. The blades are twisted at an angle of ~30° to the axis of symmetry, and are almost certainly composed of the spike S1 domain.

![Fig. 3.3 3D reconstructions presented as shaded surfaces are shown from the side (upper) and end-on (lower) perspectives. Cryo-EM reconstruction of the SARS-CoV spike (a), and SARS-CoV spike–ACE2 complex (b). (c) The atomic resolution structures were docked within the SARS-CoV spike–ACE2 3D reconstruction; PDB ID code: 2AJF (ACE2, blue; receptor-binding domain, red), and 2FXP (yellow). The arrow points to the C terminus of ACE2. Color scheme: ACE2, violet; spike, green; stalk, blue; envelope, beige; nucleocapsid, red. Scale bar: 100 Å.](image)
ACE2 binding does not result in a fundamental structural unfolding of the spike. However, the overall height of the spike was reduced from 160 Å to 150 Å following binding. When viewed end-on, the spike undergoes a rotation of ~5° following binding, and the mass at the center of the axis of symmetry on the distal end of the spike redistributes itself. These redistributions of mass were further identified in difference maps between the two reconstructions (Fig. 3.4). Upon ACE2 binding the spike undergoes a decondensation of mass around the central axis (Fig. 3.4b,g; blue). This region is the putative location of the S2 domain. The difference map for the bound spike (Fig. 3.4d,i) shows changes in both the ACE2 component (purple) and the outer edges of the three “blades” of the S1 domain (green).

The precise location of ACE2 binding on the distal end of the spike is centered at 70 Å from the central axis of the spike, with a 30 Å gap between the axis of symmetry and ACE2. One ACE2 molecule can bind to each of the three propeller-like blades of the spike, making a structure 220 Å high (Fig. 3.3b). Binding of more than one ACE2 to each spike (on one or both of the other two propeller blades of each trimer) is possible, hence binding of one ACE2 molecule does not stearically hinder binding of additional ACE2 molecules.

The cryo-EM 3D structures of the spike and the spike–ACE2 complex, when combined with the atomic resolution structures of the SARS-CoV spike receptor-binding domain – ACE2 complex (Li et al. 2005a) and the heptad repeat pre- and postfusion cores (Supekar et al. 2004; Hakansson-McReynolds et al. 2006), show that the receptor-binding domain docks to the distal end of the spike with ACE2...
filling the extra mass on the spike (shown by the color violet in Fig. 3.3). The empty upper region of the mass appears to be components of the second ACE2 and the Fc component of the chimeric protein, and the location of the C-terminus of the docked ACE2 was consistent with this interpretation.

3.3 Viral Membrane Fusion in SARS-CoV

Viral membrane fusion proteins are responsible both for binding to cellular receptors, and the subsequent fusion of viral and cellular membranes. The paradigm for type 1 fusion proteins consists of two heptad repeat regions, and a hydrophobic fusion peptide (Dutch et al. 2000). This motif is present in SARS-CoV (Hakansson-McReynolds et al. 2006) and other coronaviruses (Xu et al. 2004), as well as the hemagglutinin (HA) of influenza (Skehel and Wiley 2000), gp21 of human T-cell leukemia virus type 1 (Kobe et al. 1999), gp41 of HIV (Weissenhorn et al. 1997), GP2 of Ebola (Weissenhorn et al. 1998; Malashkevich et al. 1999), and the fusion protein of paramyxovirus (Zhao et al. 2000; Chen et al. 2001). Type 1 viral fusion proteins can also be divided into two subtypes: those whose fusion mechanism is low pH-dependent such as influenza HA, and those that are pH-independent like the retroviral fusion proteins. In retroviruses, receptor binding itself can trigger fusion, with temperature and redox conditions also influencing the fusion mechanism (Hernandez et al. 1997; Damico et al. 1998). The SARS-CoV spike appears to be insensitive to redox conditions (Fenouillet et al. 2007). Although the factors which trigger fusion (endocytosis, pH sensitivity, single receptor vs. primary and coreceptor binding, redox change) differ amongst diverse virus families, all viral fusion proteins are thought to share the same basic fusion mechanism (Baker et al. 1999; Skehel and Wiley 2000; Dutch et al. 2000; Colman and Lawrence 2003; Dimitrov 2004; Hofmann and Pohlmann 2004).

The precise mechanisms by which type 1 viral fusion proteins gain access to the host cell remain unknown. The hypothetical entry process includes several steps that take place in sequence: receptor binding, fusion core rearrangement, fusion peptide insertion in host cell membrane, refolding of heptad repeats, membrane fusion, and finally viral nucleocapsid transfer (Earp et al. 2005).

3.4 Cellular Attachment and Entry of SARS-CoV

In most proposed models of membrane fusion it is postulated that the S1 domain or analogous receptor-binding domains dissociate from the spike during the membrane fusion process. This dynamic process was demonstrated for influenza HA by Kemble et al. (1992) in their investigation where they engineered intermonomer disulfide bonds between the HA S1 subunits. The result of this was that fusion activity was impaired; however it could be restored under reducing conditions. It is
probable that the SARS-CoV spike shares a similar mechanism, with the structural changes detected by cryo-EM representing the initial step in this process.

By analogy with other type 1 viral fusion proteins, the fusion core of the SARS-CoV spike is thought to undergo similar structural rearrangements during fusion. The receptor-binding domain is localized in a position on the distal end of the molecule, closer to the 3-fold axis than anticipated, yet still in a position that would not impede these structural rearrangements. Putative mechanisms by which type 1 viral fusion proteins achieve membrane fusion have been proposed (Baker et al. 1999; Skehel and Wiley 2000; Dutch et al. 2000; Colman and Lawrence 2003; Dimitrov 2004), but complete structural evidence for the role of intermediate structures in these mechanisms has yet to be obtained. The structural biology of this process has been best characterized for the influenza HA, and paramyxovirus fusion protein (F) for which the prefusion and membrane fusion pH structures have been determined by X-ray crystallography (Sauter et al. 1992; Bullough et al. 1994; Skehel and Wiley 2000; Yin et al. 2005, 2006) (Fig. 3.5, inset). All of the subsequent models for type 1 viral fusion proteins are based on the structural data of these two fusion proteins. A drawback in all of these models is that they are based on recombinant ectodomains that are not proven to exist as a component in the complete molecule, and they lack both membrane-interacting residues and lipids (Skehel and Wiley 2000). The cryo-EM structures of intact SARS-CoV spike bound to native virion lipid envelopes are very instructive when atomic resolution fragments are docked within the overall molecule, especially as the entire SARS-CoV spike has proven to be a difficult subject for X-ray crystallography, and atomic resolution data exist for only a few fragments of the SARS-CoV spike. This structural data has been modeled into a scheme to propose a mechanism for SARS-CoV spike-mediated membrane fusion (Figs. 3.5 and 3.6). In the initial step the receptor-binding domain of the spike attaches to its human receptor ACE2. At this point the fusion core is in the prefusion configuration with the three heptad 2 repeats (HR2) forming a coiled-coil symmetric trimer at the center of the stalk of the spike (Hakansson-McReynolds et al. 2006).

During the next step of the membrane fusion process the virus is internalized in the cell by endocytosis and is exposed to a low pH environment, and may undergo proteolytic cleavage between the S1 and S2 domains (Simmons et al. 2005). The next step is fusion core rearrangement, so that the fusion peptide (FP) inserts into the host cell membrane. In Fig. 3.5 this initial process is illustrated with models M0–M3, based on the atomic structure of the HR2 prefusion core, which begins to collapse upon itself in model M3 in a manner similar to that which occurs with influenza HA (Skehel and Wiley 2000). The inset in Fig. 3.5 illustrates this process in HA by coloring segments of S2 to illustrate the rearrangement from M0 to M3 that takes place. During this process we propose that the receptor-binding domain still holds on to ACE2 so that the fully extended fusion peptide will be positioned to penetrate through the host membrane. Our cryo-EM results show that it is possible for the spike to attach to three ACE2 receptors at once; this may serve to hold on to the host membrane like a tripod so as to accurately orientate the fusion core (Fig. 3.7). In addition the 30 Å gap between the axis of symmetry and ACE2
provides sufficient space for fusion core rearrangement. Damico et al. (1998) demonstrated that the kinetics of binding of the Rous sarcoma virus envelope protein ectodomain to liposomes was not linear with respect to receptor concentration. This suggested that activation of the trimeric ectodomain favored binding to multiple receptor monomers. One can therefore infer that other structurally homologous viral envelope proteins can also bind multiple receptors, which may be a general adaptation that provides the correct temporal and spatial arrangement to bring about membrane fusion. The observation that the SARS-CoV spike could bind three soluble ACE2 receptors provides three possible binding states with one, two or three membrane-bound receptors attached to the spike. In Fig. 3.7 we present these three states; with only one receptor bound the spike and virus have a wide range of movement possible, whereas with two receptors bound the movement is

Fig. 3.5 Seven models (M0–M6) are presented which show the hypothetical rearrangement of the SARS-CoV fusion core which takes place during membrane fusion. For simplicity we show only one of the three HR1/HR2 structures for each cylindrical model. Models were constructed based on the structures for influenza HA, presented in the inset at the same scale. The cryo-EM, docked ACE2–receptor-binding domain, and prefusion core (M0) and postfusion core (M6) structures provided start and end points for modeling spike rearrangement. Five intermediate models illustrate the “jack-knife” mechanism of the fusion core. The following color scheme was used: cryo-EM surface: same as in Fig. 3.3. Ribbon structures: ACE2, white (C terminus blue; spike receptor-binding domain, red; HR1, pink; HR2, yellow. Cylindrical models: FP, red; HR1, pink; HR2, yellow. Scale bar: 100 Å
greatly restricted to motion in one plane only. Only in the case of three bound receptors will the spike and its fusion core be arranged perpendicular to the cell surface with minimal movement possible. At present it has not been demonstrated that membrane fusion requires the fusion core to be oriented perpendicular to the host cell membrane to function. However, one can hypothesize this based on the orientation of ACE2 on the distal end of the SARS-CoV spike. It is interesting to note that binding to three receptor molecules is the minimum number of binding events required to achieve this perpendicular orientation in 3D space. This observation matches up with the conserved trimeric structures of type 1 fusion proteins which are common amongst enveloped viruses, thus indicating that a possible conserved structural–functional relationship may exist.

Fig. 3.6 A schematic of the SARS-CoV spike protein with the location of the known atomic structures is presented in (a). The following abbreviations are used: RBD, receptor-binding domain; FP: fusion peptide; HR1: heptad repeat 1; HR2: heptad repeat 2; TM: transmembrane; CY: cytoplasmic tail. There are several steps involved in viral entry; they can be broken down into at least six components: (b) receptor targeting, (c) viral attachment, (d) fusion core rearrangement and fusion peptide insertion, (e) fusion core refolding, (f) membrane fusion, and (g) nucleocapsid transfer. In (b–g) the host membrane is represented using a shaded blue line. The color scheme used is the same as in Figs. 3.3 and 3.5. Scale bar: 100 Å
The next step in the membrane fusion process involves the refolding of the fusion core back upon itself to adopt the postfusion configuration (Supekard et al. 2004) (Fig. 3.5; models M4–M6). In this configuration three heptad 1 repeats (HR1) form a parallel coiled-coil trimer, and the three HR2 pack in an antiparallel fashion in the hydrophobic grooves of the HR1 trimer. The result of this is that both the FP and transmembrane regions of the spike are brought in close proximity to each other, resulting in the host and viral membranes being in close contact. Each SARS-CoV virion has an average of 65 spikes (Beniac et al. 2006). At this density, several spikes would be close enough together to act in concert to disrupt the plasma membrane and induce pore formation between viral and cellular membranes. Opening of these pores would allow the SARS-CoV nucleocapsid to enter the host cell cytoplasm, as shown in our model in Fig. 3.6. Multiple SARS-CoV spike trimers may be involved in formation of the fusion pore, similar to the situation in influenza, where it has been suggested that between three and six HA trimers may be involved in the production of each fusion pore (Skehel and Wiley 2000). In Figs. 3.5 and 3.6 we have presented the ACE2–SARS:S1 domains as they

---

**Fig. 3.7** The binding of the SARS-CoV spike to multiple receptors is presented from three 90° orthographic views (X, Y, and Z axes). When one receptor is bound there is a wide range of motion possible (a). By binding two receptors the freedom of movement is greatly reduced to motion in one plane (b). When three receptors are bound, the spike is positioned in such a way that movement is restrained and the fusion core is perpendicular to the host cell membrane (c). The host membrane is represented using a shaded blue surface (same as in Fig. 3.6), and the color scheme used for the SARS-CoV spike is the same as in Fig. 3.3. Scale bar: 100 Å
were solved in this cryo-EM investigation, for the model of membrane fusion that we present. For other fusion proteins like influenza HA1 and HIV GP120 it has been modeled that the rearrangements upon membrane fusion are dramatic involving a shedding of the above-mentioned domains. The cryo-EM investigations have detected structural movement of S1 upon ACE2 binding, which could represent the initial phase of this dramatic process that is postulated to occur in the course of membrane fusion.

An analysis of the structure of the spike–receptor complex demonstrates how SARS-CoV can adapt to utilize receptors from different species and how they may evolve to gain specificity for new receptor types, in that there is redundancy and a great deal of protein mass that can accommodate evolutionary changes. RNA viruses have a high rate of mutation and recombination (Moya et al. 2004). In SARS-CoV the spike is able to retain specific binding affinity for the ACE2 of more than one host species, and rapid evolution to gain specificity for novel ACE2 species has been demonstrated (Li et al. 2005b, 2006). The large size of the spike of coronaviruses may be related to the use of large host cell-surface molecules such as ACE2 as specific receptors. Amongst the coronavirus family, specific cell-surface receptors for the S protein are all in the range of 60–110 kD (Wentworth and Holmes 2001). These large host receptor molecules are of course functionally constrained and, in turn, relatively well conserved across species barriers. In utilizing binding to a large receptor molecule, the spike S1 domain also acts as a “spacer arm” holding the receptor far enough away from the threefold axis of symmetry of the spike S2 domain to permit fusion core rearrangement and subsequent membrane fusion. Such a property necessitates having a large spike molecule. Moreover, multiple receptor binding can have functional significance, enhancing the binding and entry of viruses. Cross-linking of adjacent host receptor molecules could increase the affinity of the virus for its target cell, as well as improving the kinetics of fusion. The SARS-CoV spike is a useful model system for the investigation of type 1 viral fusion protein dynamics. Utilizing this system for further research may lead to the possibility of developing broad-spectrum antivirals that target conserved cell fusion mechanisms shared by diverse virus families.

References

Baker KA, Dutch RE, Lamb RA, Jardetzky TS (1999) Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 3:309–319
Beaudette FW, Hudson CB (1937) Cultivation of the virus of infectious bronchitis. J Am Vet Med Assoc 90:51–60
Beniac DR, Andonov A, Grudeski E, Booth TF (2006) Architecture of the SARS coronavirus prefusion spike. Nat Struct Mol Biol 13:751–752
Beniac DR, DeVarennes SL, Andonov A, He R, Booth TF (2007) Conformational reorganization of the SARS Coronavirus spike following receptor binding: implications for membrane fusion. PLoS ONE 2(10):e1082. doi:10.1371/journal.pone.0001082
Booth TF, Kournikakis B, Bastien N, Ho J, Kobasa D, Stadnyk L, Li Y, Spence M, Paton S, Henry B, Mederski B, White D, Low DE, McGeer A, Simor A, Vearncombe M, Downey J, Jamieson FB, Tang P, Plummer F (2005) Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 191:1472–1477

Bullough PA, Hughson FM, Skehel JJ, Wiley DC (1994) Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371:37–43

Cheevers FS, Daniels JB (1949) A murine virus (JHM) causing disseminated encephalomyelitis with extensive destruction of myelin. J Exp Med 90:181–210

Chen L, Gorman JJ, McKimm-Breschkin J, Lawrence LJ, Tulloch PA, Smith BJ, Colman PM, Lawrence MC (2001) The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel paradigm for the molecular mechanism of membrane fusion. Structure 9:255–266

Colman PM, Lawrence MC (2003) The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 2:109–122

Dmitrov DS (2004) Virus entry: molecular mechanisms and biomedical applications. Nat Rev Microbiol 2:109–122

Dutch RE, Jardetzky TS, Lamb RA (2000) Virus membrane fusion proteins: biological machines that undergo a metamorphosis. Biosci Rep 20:597–612

Earp LJ, Delos SE, Park HE, White JM (2005) The many mechanisms of viral membrane fusion proteins. Curr Top Microbiol Immunol 285:25–66

Fenouillet E, Barbouche R, Jones IM (2007) Cell entry by enveloped viruses: redox considerations for HIV and SARS-Coronavirus. Antioxid Redox Signal 9:1009–1034

Frank J, Radermacher M, Penczek P, Zhu J, Li Y, Ladjadj M, Leith A (1996) SPIDER and WEB: processing and visualization of images in 3D electron microscopy and related fields. J Struct Biol 116:190–199

Hakansson-McReynolds S, Jiang S, Rong L, Caffrey M (2006) Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state. J Biol Chem 281:11965–11971

Hernandez LD, Peters RJ, Delos SE, Young JA, Agard DA, White JM (1997) Activation of a retroviral membrane fusion protein: soluble receptor-induced liposome binding of the ALSV envelope glycoprotein. J Cell Biol 139:1455–1464

Hofmann H, Pohlmann S (2004) Cellular entry of the SARS coronavirus. Trends Microbiol 12:466–472

Kemble GW, Bodian DL, Rose J, Wilson IA, White JM (1992) Intermonomer disulfide bonds impair the fusion activity of influenza virus hemagglutinin. J Virol 66:4940–4950

Kobe B, Center RJ, Kemp BE, Poumbourios P (1999) Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl Acad Sci USA 96:4319–4324

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450–454

Li F, Li W, Farzan M, Harrison SC (2005a) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309:1864–1868

Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M (2005b) Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 24:1634–1643

Li W, Wong SK, Li F, Kuhn JH, Huang IC, Choe H, Farzan M (2006) Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions. J Virol 80:4211–4219
Malashkevich VN, Schneider BJ, McNally ML, Milhollen MA, Pang JX, Kim PS (1999) Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc Natl Acad Sci USA 96:2662–2667

Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, Butterfield YS, Khattra J, Asano JK, Barber SA, Chan SY, Cloutier A, Coughlin SM, Freeman D, Ginn N, Griffith OL, Leach SR, Mayo M, McDonald H, Montgomery SB, Pandoh PK, Petrescu AS, Robertson AG, Schein JE, Siddiqui A, Smalius DE, Stott JM, Yang GS, Plummer F, Andonov A, Artsob H, Bastien N, Bernard K, Booth TF, Bowness D, Czb M, Drebout M, Fernando L, Flick R, Garbutt M, Gray M, Grolla A, Jones S, Feldmann H, Meyers A, Kabani A, Li Y, Normand S, Stroher U, Tipples GA, Tyler S, Vogrig R, Ward D, Watson B, Brunham RC, Krajden M, Petric M, Skowronski DM, Upton C, Roper RL (2003) The Genome sequence of the SARS-associated coronavirus. Science 300:1399–1404

Moya A, Holmes EC, Gonzalez-Candelas F (2004) The population genetics and evolutionary epidemiology of RNA viruses. Nat Rev Microbiol 2:279–288

Penczek PA, Grassucci RA, Frank J (1994) The ribosome at improved resolution: new techniques for merging and orientation refinement in 3D cryo-electron microscopy of biological particles. Ultramicroscopy 53:251–270

Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, Icenogle JP, Penaranda S, Bankamp B, Maher K, Chen MH, Tong S, Tamin A, Lowe L, Frace M, DeRisi JL, Chen Q, Wang D, Erdman DD, Peret TC, Burns C, Ksiazek TG, Rollin PE, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Foucher R, Gunther S, Osterhaus AD, Drosten C, Pallansch MA, Anderson LJ, Bellini WJ (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394–1399

Sauter NK, Hanson JE, Glick GD, Brown JH, Crowther RL, Park SJ, Skehel JJ, Wiley DC (1992) Binding of influenza virus hemagglutinin to analogs of its cell-surface receptor, siaic acid: analysis by proton nuclear magnetic resonance spectroscopy and X-ray crystallography. Biochemistry 31:9609–9621

Simmons G, Gosalia DN, Rennekamp AJ, Reeves JD, Diamond SL, Bates P (2005) Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA 102:11876–11881

Skehel JJ, Wiley DC (2000) Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 69:531–569

Supek PA, Bruckman C, Ingallinella P, Bianchi E, Pessi A, Carfi A (2004) Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein. Proc Natl Acad Sci USA 101:17958–17963

Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426–430

Weissenhorn W, Carfi A LKH, Skehel JJ, Wiley DC (1998) Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol Cell 2:605–616

Wentworth DE, Holmes KV (2001) Molecular determinants of species specificity in the coronavirus receptor aminopeptidase N (CD13): influence of N-linked glycosylation. J Virol 75: 9741–9752

Xu Y, Lou Z, Liu Y, Pang H, Tien P, Gao GF, Rao Z (2004) Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core. J Biol Chem 279:49414–49419

Yin HS, Paterson RG, Wen X, Lamb RA, Jardetzky TS (2005) Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein. Proc Natl Acad Sci USA 102: 9288–9293

Yin HS, Wen X, Paterson RG, Lamb RA, Jardetzky TS (2006) Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature 439:38–44

Zhao X, Singh M, Malashkevich VN, Kim PS (2000) Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci USA 97:14172–14177
Molecular Biology of the SARS-Coronavirus
Lal, S.K. (Ed.)
2010, XIII, 328 p., Hardcover
ISBN: 978-3-642-03682-8